Literature DB >> 11349939

Oxidative stress in cystic fibrosis: dietary and metabolic factors.

L G Wood1, D A Fitzgerald, P G Gibson, D M Cooper, C E Collins, M L Garg.   

Abstract

OBJECTIVE: To examine oxidative stress in CF by measuring 8-iso-PGF2alpha and antioxidant defenses, in relation to dietary intake, immune function and clinical status.
METHODS: We measured total plasma concentrations of 8-iso-PGF2alpha and dietary antioxidants (vitamin E, vitamin C, beta-carotene), erythrocyte antioxidant enzyme activities (glutathione peroxidase and superoxide dismutase), lung function and dietary intake in 21 CF subjects and 21 healthy age- and gender-matched controls.
RESULTS: Total plasma 8-iso-PGF2alpha concentration (median [quartile 1-quartile 3]) was significantly higher in CF subjects compared to controls (214 pg/mL (155-331) vs. 135 pg/mL (101-168), p = 0.001). Neutrophil, monocyte and total white cell counts were elevated in the CF group and these correlated with 8-iso-PGF2alpha concentration. Despite similar dietary intake, lower plasma antioxidant concentrations were observed in the CF group (vitamin E, p < 0.001, vitamin C, p = 0.004, beta-carotene, p = 0.001). 8-iso-PGF2alpha correlated negatively with plasma vitamin E, C and beta-carotene concentrations.
CONCLUSION: Oxidative stress is increased in CF patients, despite normal dietary antioxidant intake. The immune response appears to be a key factor causing oxidative stress. Antioxidant intervention aimed at reducing oxidative stress in CF needs to be assessed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11349939     DOI: 10.1080/07315724.2001.10719028

Source DB:  PubMed          Journal:  J Am Coll Nutr        ISSN: 0731-5724            Impact factor:   3.169


  19 in total

1.  Bioavailability of a novel, water-soluble vitamin E formulation in malabsorbing patients.

Authors:  Konstantinos Papas; John Kalbfleisch; Ricky Mohon
Journal:  Dig Dis Sci       Date:  2007-01-10       Impact factor: 3.199

2.  Evidence of microvascular dysfunction in patients with cystic fibrosis.

Authors:  Paula Rodriguez-Miguelez; Jeffrey Thomas; Nichole Seigler; Reva Crandall; Kathleen T McKie; Caralee Forseen; Ryan A Harris
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-04-15       Impact factor: 4.733

3.  Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation.

Authors:  Oana Ciofu; Bente Riis; Tacjana Pressler; Henrik Enghusen Poulsen; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

Review 4.  Cystic fibrosis-related oxidative stress and intestinal lipid disorders.

Authors:  Marie-Laure Kleme; Emile Levy
Journal:  Antioxid Redox Signal       Date:  2015-01-22       Impact factor: 8.401

5.  Activation of critical, host-induced, metabolic and stress pathways marks neutrophil entry into cystic fibrosis lungs.

Authors:  Megha Makam; Daisy Diaz; Julie Laval; Yael Gernez; Carol K Conrad; Colleen E Dunn; Zoe A Davies; Richard B Moss; Leonore A Herzenberg; Leonard A Herzenberg; Rabindra Tirouvanziam
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-17       Impact factor: 11.205

6.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

7.  High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis.

Authors:  Rabindra Tirouvanziam; Carol K Conrad; Teodoro Bottiglieri; Leonore A Herzenberg; Richard B Moss; Leonard A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-13       Impact factor: 11.205

8.  Pseudomonas aeruginosa OspR is an oxidative stress sensing regulator that affects pigment production, antibiotic resistance and dissemination during infection.

Authors:  Lefu Lan; Thomas S Murray; Barbara I Kazmierczak; Chuan He
Journal:  Mol Microbiol       Date:  2009-11-25       Impact factor: 3.501

9.  Progress in cystic fibrosis and the CF Therapeutics Development Network.

Authors:  Steven M Rowe; Drucy S Borowitz; Jane L Burns; John P Clancy; Scott H Donaldson; George Retsch-Bogart; Scott D Sagel; Bonnie W Ramsey
Journal:  Thorax       Date:  2012-10       Impact factor: 9.139

10.  Preliminary evidence for cell membrane amelioration in children with cystic fibrosis by 5-MTHF and vitamin B12 supplementation: a single arm trial.

Authors:  Cinzia Scambi; Lucia De Franceschi; Patrizia Guarini; Fabio Poli; Angela Siciliano; Patrizia Pattini; Andrea Biondani; Valentina La Verde; Oscar Bortolami; Francesco Turrini; Franco Carta; Ciro D'Orazio; Baroukh M Assael; Giovanni Faccini; Lisa M Bambara
Journal:  PLoS One       Date:  2009-03-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.